Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

Fig. 2

A–F Efficacy of amulirafusp alfa in the Lugano EFS assessed by investigators. A waterfall plot for the best percentage change from baseline measurable lesions. B spider plot for the relative change from baseline measurable lesions. C swimmer plot for the treatment duration and tumor response. D The Kaplan–Meier curve of DoR. E The Kaplan–Meier curve of PFS. F The Kaplan–Meier curve of OS. CR: complete response; CI: confidence interval; DCR: disease control rate; DoR: duration of response; EFS: efficacy set; NE: not evaluable; NR: not reached; ORR: objective response rate; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease; SPD: sum of the product of the diameters

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us